Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology

Hallmarks of Cancer: New Dimensions

Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887 · see citing works

Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · see citing works

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · see citing works

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · see citing works

Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti–PD-L1 efficacy

Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · see citing works

Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice

Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · see citing works

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · see citing works

Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403 · see citing works

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients

Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · see citing works

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Marabelle, A., Le, D. T., Ascierto, P. A., Giacomo, A. M. D., Jesus‐Acosta, A. D., Delord, J., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,077 · see citing works

Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome

Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913 · see citing works

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825 · see citing works

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

Schneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,434 · see citing works

Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: A proof-of-concept exploratory study

Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0495-2 · Cited by 2,357 · see citing works

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127 · see citing works

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781 · see citing works

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757 · see citing works

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Spigel, D. R., Faivre-Finn, C., Gray, J. E., Vicente, D., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Garassino, M. C., Hui, R., Quantin, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01308 · Cited by 1,445 · see citing works

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30700-9 · Cited by 1,399 · see citing works

Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing

Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367 · see citing works

Drug-Resistant <i>E. coli</i> Bacteremia Transmitted by Fecal Microbiota Transplant

DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R. A., Huntley, M. H., Turbett, S., Chung, R. T., Chen, Y.-B., & Hohmann, E. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910437 · Cited by 1,281 · see citing works

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Schachter, J., Ribas, A., Long, G. V., Arance, A. M., Grob, J., Mortier, L., DAUD, A. I., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,226 · see citing works

European consensus conference on faecal microbiota transplantation in clinical practice

Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207 · see citing works

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02229 · Cited by 1,159 · see citing works

A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

Tanoue, T., Morita, S., Plichta, D. R., Skelly, A. N., Suda, W., Sugiura, Y., Narushima, S., Vlamakis, H., Motoo, I., Sugita, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0878-z · Cited by 1,145 · see citing works

Untitled work

(1958) · PubMed · Cited by 978 · see citing works

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., et al. (2021) · Science · doi:10.1126/science.aaz7015 · Cited by 966 · see citing works

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908 · see citing works

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.

Provencio, M., Nadal, E., Insa, A., García-Campelo, M. R., Casal-Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., De Castro Carpeño, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30453-8 · Cited by 841 · see citing works

Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation

Peled, J. U., Gomes, A. L. C., Devlin, S. M., Littmann, E. R., Taur, Y., Sung, A. D., Weber, D., Hashimoto, D., Slingerland, A. E., Slingerland, J. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1900623 · Cited by 765 · see citing works

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740 · see citing works

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

Derosa, L., Routy, B., Thomas, A. M., Iebba, V., Zalcman, G., Friard, S., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01655-5 · Cited by 685 · see citing works

Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent <i>Clostridium difficile</i> Infection: A Randomized Clinical Trial

Lee, C. H., Steiner, T., Petrof, E. O., Smieja, M., Roscoe, D., Nematallah, A., Weese, J. S., Collins, S., Moayyedi, P., Crowther, M., et al. (2016) · JAMA · doi:10.1001/jama.2015.18098 · Cited by 627 · see citing works

Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

Pinato, D. J., Howlett, S., Ottaviani, D., Urus, H., Patel, A., Mineo, T., Brock, C., Power, D., Hatcher, O., Falconer, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2785 · Cited by 626 · see citing works

Effect of Oral Capsule– vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent <i>Clostridium difficile</i> Infection: A Randomized Clinical Trial

Kao, D., Roach, B., Silva, M., Beck, P., Rioux, K., Kaplan, G. G., Chang, H.-J., Coward, S., Goodman, K. J., Xu, H., et al. (2017) · JAMA · doi:10.1001/jama.2017.17077 · Cited by 615 · see citing works

Understanding the mechanisms of faecal microbiota transplantation

Khoruts, A., & Sadowsky, M. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.98 · Cited by 563 · see citing works

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

Korman, A. J., Garrett-Thomson, S. C., & Lönberg, N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 561 · see citing works

SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> Infection

Feuerstadt, P., Louie, T. J., Lashner, B., Wang, E. E. L., Diao, L., Bryant, J. A., Sims, M., Kraft, C. S., Cohen, S. H., Berenson, C. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2106516 · Cited by 558 · see citing works

Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy

Huang, J., Liu, D., Wang, Y., Liu, L., Li, J., Yuan, J., Jiang, Z., Jiang, Z., Hsiao, W. W., Liu, H., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-321031 · Cited by 539 · see citing works

The gut microbiota influences anticancer immunosurveillance and general health

Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0006-2 · Cited by 523 · see citing works

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01694-6 · Cited by 515 · see citing works

International consensus conference on stool banking for faecal microbiota transplantation in clinical practice

Cammarota, G., Ianiro, G., Kelly, C. R., Mullish, B. H., Allegretti, J. R., Kassam, Z., Putignani, L., Fischer, M., Keller, J. J., Costello, S. P., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319548 · Cited by 506 · see citing works

Targeting the gut and tumor microbiota in cancer

Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496 · see citing works

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

McCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., Balaji, A. K., Vetizou, M., Prescott, S. M., Fernandes, M. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01698-2 · Cited by 472 · see citing works

<i>Fusobacterium</i> in Colonic Flora and Molecular Features of Colorectal Carcinoma

Tahara, T., Yamamoto, E., Suzuki, H., Maruyama, R., Chung, W., Garriga, J., Jelinek, J., Yamano, H.-O., Sugai, T., An, B., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1865 · Cited by 465 · see citing works

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma

Lee, K. A., Thomas, A. M., Bolte, L. A., Björk, J. R., de Ruijter, L. K., Armanini, F., Asnicar, F., Blanco-Miguez, A., Board, R., Calbet-Llopart, N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01695-5 · Cited by 464 · see citing works

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

Sarnaik, A. A., Hamid, O., Khushalani, N. I., Lewis, K. D., Medina, T. M., Kluger, H. M., Thomas, S. S., Domingo‐Musibay, E., Pavlick, A. C., Whitman, E. D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00612 · Cited by 453 · see citing works

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01406-6 · Cited by 437 · see citing works

Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients

Derosa, L., Routy, B., Fidelle, M., Iebba, V., Alla, L., Pasolli, E., Segata, N., Desnoyer, A., Pietrantonio, F., Ferrere, G., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.044 · Cited by 398 · see citing works

Fecal microbiota transplantation to maintain remission in Crohn's disease: A pilot randomized controlled study

Saint-Antoine IBD Network, Sokol, H., Landman, C., Seksik, P., Berard, L., Montil, M., Nion-Larmurier, I., Bourrier, A., Le Gall, G., Lalande, V., et al. (2020) · Microbiome · doi:10.1186/s40168-020-0792-5 · Cited by 378 · see citing works

Moving towards personalized treatments of immune-related adverse events

Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351 · see citing works

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01702-9 · Cited by 349 · see citing works

Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial

Craven, L. J., Rahman, A., Parvathy, S. N., Beaton, M. D., Silverman, J. D., Qumosani, K. M., HRAMIAK, I. M., Hegele, R., JOY, T. R., Meddings, J. B., et al. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000661 · Cited by 346 · see citing works

The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer

Hakozaki, T., Richard, C., Elkrief, A., Hosomi, Y., Benlaïfaoui, M., Mimpen, I., Terrisse, S., Derosa, L., Zitvogel, L., Routy, B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0196 · Cited by 316 · see citing works

Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis

Baunwall, S. M. D., Lee, M. M., Eriksen, M. K., Mullish, B. H., Marchesi, J. R., Dahlerup, J. F., & Hvas, C. L. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100642 · Cited by 302 · see citing works

A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota

Messaoudene, M., Pidgeon, R., Richard, C., Ponce, M., Diop, K., Benlaifaoui, M., Nolin-Lapalme, A., Cauchois, F., Malo, J., Belkaid, W., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0808 · Cited by 250 · see citing works

Fecal Microbial Transplant Effect on Clinical Outcomes and Fecal Microbiome in Active Crohnʼs Disease

Suskind, D. L., Brittnacher, M. J., Wahbeh, G., Shaffer, M. L., Hayden, H. S., Qin, X., Singh, N., Damman, C. J., Hager, K. R., Nielson, H., et al. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000307 · Cited by 243 · see citing works

Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer

Zhang, S., Mao, Y., Zhang, Z.-Y., Li, Z., Kong, C., Chen, H., Cai, P., Han, B., Ye, T., & Wang, L. (2021) · Theranostics · doi:10.7150/thno.54476 · Cited by 231 · see citing works

Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohnʼs Disease

Vaughn, B. P., Vatanen, T., Allegretti, J. R., Bai, A., Xavier, R. J., Korzenik, J. R., Gevers, D., Ting, A., Robson, S. C., & Moss, A. C. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000893 · Cited by 229 · see citing works

Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?

Derosa, L., Routy, B., Desilets, A., Daillère, R., Terrisse, S., Kroemer, G., & Zitvogel, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0236 · Cited by 170 · see citing works

Recipient factors in faecal microbiota transplantation: one stool does not fit all

Danne, C., Rolhion, N., & Sokol, H. (2021) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-021-00441-5 · Cited by 154 · see citing works

Donor Recruitment for Fecal Microbiota Transplantation

Paramsothy, S., Borody, T. J., Lin, E., Finlayson, S., Walsh, A. J., Samuel, D., van den Bogaerde, J., Leong, R. W. L., Connor, S. J., Ng, W., et al. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000405 · Cited by 149 · see citing works

Reorganisation of Faecal Microbiota Transplant Services During the COVID-19 Pandemic

Ianiro, G., Mullish, B. H., Kelly, C. R., Kassam, Z., Kuijper, E. J., Ng, S. C., Iqbal, T. H., Allegretti, J. R., Bibbò, S., Sokol, H., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-321829 · Cited by 147 · see citing works

Butyrate acts through HDAC inhibition to enhance aryl hydrocarbon receptor activation by gut microbiota-derived ligands

Modoux, M., Rolhion, N., Lefèvre, J. H., Oeuvray, C., Nádvorník, P., Illéš, P., Emond, P., Parc, Y. R., Mani, S., Dvořák, Z., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2105637 · Cited by 145 · see citing works

Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma

Ianiro, G., Rossi, E., Thomas, A. M., Schinzari, G., Masucci, L., Quaranta, G., Settanni, C. R., Lopetuso, L. R., Armanini, F., Blanco‐Míguez, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18127-y · Cited by 139 · see citing works

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

Arance, A. M., de la Cruz‐Merino, L., Petrella, T. M., Jamal, R., Ny, L., Carneiro, A., Berrocal, A., Márquez‐Rodas, I., Spreafico, A., Atkinson, V. G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00221 · Cited by 133 · see citing works

Leaky Gut in IBD: Intestinal Barrier–Gut Microbiota Interaction

Yu, S., Sun, Y., Shao, X., Zhou, Y., Yu, Y., Kuai, X., & Zhou, C. (2022) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2203.03022 · Cited by 127 · see citing works

Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis

Yonekura, S., Terrisse, S., Alves Costa Silva, C., Lafarge, A., Iebba, V., Ferrere, G., Goubet, A.-G., Fahrner, J.-E., Lahmar, I., Ueda, K., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0999 · Cited by 112 · see citing works

Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns

Pamer, E. G. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.117 · Cited by 109 · see citing works

Establishing a Fecal Microbiota Transplant Service for the Treatment ofClostridium difficileInfection

Costello, S. P., Tucker, E. C., LaBrooy, J. T., Schoeman, M., & Andrews, J. M. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ994 · Cited by 105 · see citing works

The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey

Baunwall, S. M. D., Terveer, E. M., Dahlerup, J. F., Erikstrup, C., Arkkila, P. E. T., Vehreschild, M. J. G. T., Ianiro, G., Gasbarrini, A., Sokol, H., Kump, P. K., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100181 · Cited by 100 · see citing works

Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab

Hopkins, A. M., Kichenadasse, G., Karapetis, C. S., Rowland, A., & Sorich, M. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1876 · Cited by 88 · see citing works

Fecal microbiota transplantation is safe and tolerable in patients with multiple sclerosis: A pilot randomized controlled trial

Al, K. F., Craven, L. J., Gibbons, S., Parvathy, S. N., Wing, A. C., Graf, C., Parham, K. A., Kerfoot, S. M., Wilcox, H., Burton, J. P., et al. (2022) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173221086662 · Cited by 82 · see citing works

Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer

Huang, J., Xing, Z., Kang, W., Hao, H., Mao, Y., Zhang, H., Chen, Y., Tan, Y. Q., He, Y., Zhao, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.874922 · Cited by 81 · see citing works

Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches

Thompson, E. A., & Powell, J. D. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-023155 · Cited by 80 · see citing works

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

Desîlets, A., Blanc‐Durand, F., Lau, S. C. M., Hakozaki, T., Kitadai, R., Malo, J., Belkaïd, W., Richard, C., Messaoudene, M., Cvetkovic, L., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.008 · Cited by 78 · see citing works

Low Level Engraftment and Improvement following a Single Colonoscopic Administration of Fecal Microbiota to Patients with Ulcerative Colitis

Damman, C. J., Brittnacher, M., Westerhoff, M. A., Hayden, H. S., Radey, M. C., Hager, K. R., Marquis, S. R., Miller, S. I., & Zisman, T. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133925 · Cited by 73 · see citing works

Oral Capsulized Fecal Microbiota Transplantation for Eradication of Carbapenemase-producing Enterobacteriaceae Colonization With a Metagenomic Perspective

Bar‐Yoseph, H., Carasso, S., Shklar, S., Korytny, A., Dar, R. E., Daoud, H., Nassar, R., Maharshak, N., Hussein, K., Geffen, Y., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa737 · Cited by 70 · see citing works

Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites

Martínez-Gili, L., McDonald, J. A. K., Liu, Z., Kao, D. H., Allegretti, J. R., Monaghan, T. M., Barker, G. F., Blanco, J. M., Williams, H. R. T., Holmes, E. C., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1810531 · Cited by 62 · see citing works

Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

Rutkowski, P. L., Indini, A., Luca, M. D., Merelli, B., Mariuk-Jarema, A., Teterycz, P., Rogala, P., Lugowska, I. A., Cybulska-Stopa, B., Labianca, A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001117 · Cited by 62 · see citing works

Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome

Goll, R., Johnsen, P. H., Hjerde, E., Diab, J., Valle, P. C., Hilpüsch, F., & Cavanagh, J. P. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1794263 · Cited by 60 · see citing works

Extended Screening Costs Associated With Selecting Donors for Fecal Microbiota Transplantation for Treatment of Metabolic Syndrome-Associated Diseases

Craven, L. J., Parvathy, S. N., Tat-Ko, J., Burton, J. P., & Silverman, M. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx243 · Cited by 56 · see citing works

Repurposing Metformin in Nondiabetic People With HIV: Influence on Weight and Gut Microbiota

Isnard, S., Lin, J., Fombuena, B., Ouyang, J., Varin, T. V., Richard, C., Marette, A., Ramendra, R., Planas, D., Raymond Marchand, L., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa338 · Cited by 51 · see citing works

Optimal screening and donor management in a public stool bank

Kazerouni, A., Burgess, J., Burns, L. J., & Wein, L. M. (2015) · Microbiome · doi:10.1186/s40168-015-0140-3 · Cited by 43 · see citing works

Fecal Transplant in Children With Clostridioides difficile Gives Sustained Reduction in Antimicrobial Resistance and Potential Pathogen Burden

Hourigan, S. K., Ahn, M., Gibson, K. M., Pérez‐Losada, M., Felix, G., Weidner, M., Leibowitz, I., Niederhuber, J. E., Sears, C. L., Crandall, K. A., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz379 · Cited by 43 · see citing works

Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma

Ninkov, M., Schmerk, C. L., Moradizadeh, M., Parvathy, S. N., Figueredo, R., Burton, J. P., Silverman, M., Fernandes, R., Vareki, S. M., & Haeryfar, S. M. M. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03329-8 · Cited by 32 · see citing works

Metagenomic Characterization of Gut Microbiota of Carriers of Extended-Spectrum Beta-Lactamase or Carbapenemase-Producing Enterobacteriaceae Following Treatment with Oral Antibiotics and Fecal Microbiota Transplantation: Results from a Multicenter Randomized Trial

Léo, S., Lazarević, V., Girard, M., Gaïa, N., Schrenzel, J., LASTOURS, V. D., Fantin, B., Bonten, M. J. M., Carmeli, Y., Rondinaud, E., et al. (2020) · Microorganisms · doi:10.3390/microorganisms8060941 · Cited by 31 · see citing works

Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors

Shaikh, F. Y., Gills, J. J., Mohammad, F., White, J. R., Stevens, C. M., Ding, H., Fu, J., Tam, A., Blosser, R. L., Domingue, J. C., et al. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-022-03169-6 · Cited by 30 · see citing works

Fecal Microbiota Transplantation Effectively Cures a Patient With Severe Bleeding Immune Checkpoint Inhibitor-Associated Colitis and a Short Review

Chen, M.-M., Liu, M., Li, C., Peng, S., Li, Y., Xu, X., Sun, M., & Sun, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.913217 · Cited by 29 · see citing works

First clinical proof-of-concept that FMT can overcome resistance to ICIs

Elkrief, A., & Routy, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00502-3 · Cited by 23 · see citing works

Roche’s anti-TIGIT drug suffers a phase III cancer setback

Mullard, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00068-4 · Cited by 21 · see citing works

AACR Cancer Progress Report 2022: Decoding Cancer Complexity, Integrating Science, and Transforming Patient Outcomes

Williams, P. A., Zaidi, S. K., & Sengupta, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2588 · Cited by 21 · see citing works

Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer

Katayama, Y., Yamada, T., Tanimura, K., Yoshimura, A., Takeda, T., Chihara, Y., Tamiya, N., Kaneko, Y., Uchino, J., & Takayama, K. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12969 · Cited by 20 · see citing works

Fecal microbiota transplantation (FMT) for immune checkpoint inhibitor induced–colitis (IMC) refractory to immunosuppressive therapy.

Wang, Y., Ma, W., Abu‐Sbeih, H., Jiang, Z., & DuPont, H. L. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3067 · Cited by 19 · see citing works

Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC).

Mok, T. S. K., Wu, Y.-L. L. C., Watson Patricia, A., Zhang, J., Rangwala, R. A., & Junior, G. L. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps8105 · Cited by 17 · see citing works

Refractory Immune Checkpoint Inhibitor-induced Colitis Improved by Fecal Microbiota Transplantation: A Case Report

Dai, C., & Liu, W.-X. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab265 · Cited by 17 · see citing works

Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study.

Fernandes, R., Parvathy, S. N., Ernst, D. S., Haeryfar, M., Burton, J. P., Silverman, M., & Maleki, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.4553 · Cited by 17 · see citing works

Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel

Ianiro, G., Mullish, B. H., Iqbal, T. H., Terveer, E. M., Baunwall, S. M. D., Link, A., Sokol, H., Kupčinskas, J., Masucci, L., Sanguinetti, M., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00305-3 · Cited by 15 · see citing works

Fecal microbiota transplantation followed by anti–PD-1 treatment in patients with advanced melanoma.

Miller, W. H., Routy, B., Jamal, R., Ernst, D. S., Logan, D., Esfahani, K., Bélanger, K., Elkrief, A., Lapointe, R., Thébault, P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.9533 · Cited by 11 · see citing works

Enhanced donor screening for faecal microbial transplantation during COVID-19

Parvathy, S. N., Lenehan, J. G., Fernandes, R., Poutanen, S. M., Hota, S. S., Vareki, S. M., & Silverman, M. E. (2021) · Gut · doi:10.1136/gutjnl-2021-324593 · Cited by 10 · see citing works

The Role of Fecal Microbiota Transplantation in IBD

Fanizzi, F., D’Amico, F., Bombassaro, I., Zilli, A., Furfaro, F., Parigi, T. L., Cicerone, C., Fiorino, G., Peyrin‐Biroulet, L., Danese, S., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12091755 · Cited by 48 · see citing works

Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)

Jiang, H., & Zhang, Q. (2024) · Oncology Letters · doi:10.3892/ol.2024.14221 · Cited by 34 · see citing works

Effects of Vitamin E on the Gut Microbiome in Ageing and Its Relationship with Age-Related Diseases: A Review of the Current Literature

Gothandapani, D., & Makpol, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914667 · Cited by 27 · see citing works

Gut modulation to regulate NF-κB in colorectal and gastric cancer therapy and inflammation

Kearns, R. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04118-9 · Cited by 23 · see citing works

Unraveling the complexities of colorectal cancer and its promising therapies – An updated review

Saha, S., Ghosh, S., Ghosh, S., Nandi, S., & Nayak, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113325 · Cited by 23 · see citing works

Microbiota-centered interventions to boost immune checkpoint blockade therapies

Almonte, A. A., Thomas, S., & Zitvogel, L. (2025) · Journal of Experimental Medicine · doi:10.1084/jem.20250378 · Cited by 19 · see citing works

Fecal Microbiota Transplantation for Weight and Glycemic Control of Obesity as Well as the Associated Metabolic Diseases: Meta-Analysis and Comprehensive Assessment

Hu, D., Zhao, J., Zhang, H., Wang, G., & Gu, Z. (2023) · Life · doi:10.3390/life13071488 · Cited by 16 · see citing works

Fungi and cancer: unveiling the complex role of fungal infections in tumor biology and therapeutic resistance

Zhang, W., Zhang, H., Gao, Y., Lei, J., & Suo, C. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1596688 · Cited by 12 · see citing works

Intratumoral microbiota for hepatocellular carcinoma: from preclinical mechanisms to clinical cancer treatment

Chen, M., & Bie, L. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03745-7 · Cited by 10 · see citing works

Communication between gut microbiota-derived metabolites and the tumor microenvironment

Hu, X., Li, B., Li, Y., Liang, Y., & Huang, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1649438 · Cited by 10 · see citing works

Clinical efficacy of washed microbiota transplantation on metabolic syndrome and metabolic profile of donor outer membrane vesicles

Hu, X., Wu, Q., Huang, L., Xu, J., He, X., & Wu, L. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1465499 · Cited by 8 · see citing works

Effect of Probiotics and Fecal Microbiota Transplantation in Dirty Rats with Established Primary Liver Cancer

Cao, Y., Zhang, L., Xiong, F., Guo, X., Kan, X., Song, S., Liang, B., Liang, B., Li, Y., & Zheng, C. (2023) · Future Microbiology · doi:10.2217/fmb-2022-0234 · Cited by 8 · see citing works

Novel Microbial Engraftment Trajectories Following Microbiota Transplant Therapy in Ulcerative Colitis

Moutsoglou, D., Syal, A., Lopez, S., Nelson, E. C., Chen, L., Kabage, A. J., Fischer, M., Khoruts, A., Vaughn, B. P., & Staley, C. M. (2024) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjae142 · Cited by 8 · see citing works

Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy

Hu, J., Feng, T., Zhang, L., Zhou, Q., & Zhu, L. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003687 · Cited by 7 · see citing works

Immunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope

Brancewicz, J., Padzińska-Pruszyńska, I. B., Kubiak, M., & Kucharzewska, P. (2025) · Cells · doi:10.3390/cells14130995 · Cited by 6 · see citing works

The role of microbiota in gastric cancer: A comprehensive review

Lei, C., Xu, Y., Zhang, S., Huang, C., & Qin, J. (2024) · Helicobacter · doi:10.1111/hel.13071 · Cited by 6 · see citing works

Fecal microbiota transplantation: from empirical remedy to precision medicine

Zhao, J., 樊翌明, Yang, K., & Gao, H. (2026) · Frontiers in Microbiomes · doi:10.3389/frmbi.2026.1863308 · Cited by 6 · see citing works

Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies

Yu, Y., Guo, Z., Luo, Z., Dian, Y., Yang, X., Chen, X., Zeng, F., & Deng, G. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00473-w · Cited by 4 · see citing works

Breaching the immune-cold barrier in pMMR/MSS metastatic colorectal cancer: emerging strategies beyond standard care

Kang, W., Zhang, Z., Li, W., Zhang, Q., Li, N., Jiang, Y., Zhang, J., & He, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773002 · Cited by 3 · see citing works

Gut microbiota and metabolites: emerging prospects in the treatment of non-small cell lung cancer

Jiao, J.-M., Liu, C., Zang, D., & Chen, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1638942 · Cited by 2 · see citing works

Assessing the Safety and Efficacy of Fecal Microbiota Transplantation for Severe Chemotherapy‐Induced Diarrhea in Colorectal Cancer Patients: A Single‐Arm Clinical Trial

Alnaggar, M., Mahyoub, M. A., Cheng, W., Huang, W., Xu, Y., Wang, S., Chen, T., & Alshorman, J. (2025) · International Journal of Clinical Practice · doi:10.1155/ijcp/8052716 · Cited by 2 · see citing works

The gut microbiome in colorectal cancer: molecular paradigms and translational frontiers

Liu, Y., & Mei, D. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1864299 · Cited by 2 · see citing works

Immune checkpoint inhibitors in dMMR-MSI-H colorectal cancer: rationale, progress and prospects

Xu, G., Liang, D., Li, L. S., Cheng, J., & Wang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1828717 · Cited by 2 · see citing works

Harnessing the gut microbiota to enhance immune checkpoint inhibitor efficacy: from mechanistic insights to clinical translation

Bi, Q., Zhang, L., Wan, H., & Zhang, J. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11988-4 · Cited by 1 · see citing works

Fecal Microbiota Transplantation from Exercise-Preconditioned Mice Attenuates Post-stroke Cognitive Impairment by Preserving Gut and Blood-Brain Barrier Integrity

Yu, Y., Tian, M., Sun, S., Wang, H., Qin, M., Gao, Y., Jia, X., Gao, Q., & Jiang, F. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04780-0 · Cited by 2 · see citing works

Safety and efficacy of fecal microbiota transplantation for cytotoxic chemotherapy– induced diarrhea management in patients with colorectal cancer: a single-arm clinical trialPreprint

Alnaggar, M., Mahyoub, M. A., Cheng, W. J., Huang, W., Xu, Y., Wang, S., Alshorman, J., & Chen, T. (2024) · Research Square · doi:10.21203/rs.3.rs-4373410/v1

Gut Microbiota and Immune Checkpoint Inhibitors: A Synergistic Approach in Hepatocellular Carcinoma Therapy

Huang, Y.-C., Tsai, K.-H., Tsai, J.-C., Peng, W.-H., Lai, C.-Y., Kao, Y.-C., & Wu, L.-L. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1013767

Gut microbiota and ulcerative colitis: a bibliometric analysis of knowledge structure, research hotspots, and future directions

Zhang, Z., Hu, X., & Ma, Y. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1765748

Gut microbiota modulation for enhanced efficacy and reduced toxicity of chemotherapy in pediatric acute leukemias: a review

Murtazin, A. A., Islamgulov, A. K., & Malievsky, V. A. (2026) · Consilium Medicum · doi:10.26442/20751753.2026.5.203517

Novel options for the management of C. difficile : a look into the future

Granata, G., Petrosillo, N., & Taglietti, F. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2739273

Inflammatory bowel disease and breast cancer: epidemiological evidence, shared biology, and clinical management

Han, Q., 张潇潇, & Li, S. (2026) · Inflammation Research · doi:10.1007/s00011-026-02390-8

Cultivating the microbiome to enhance cancer immunotherapy

Baruch, E. N., Ajami, N. J., & Wargo, J. A. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01146-x

Microbial engraftment and immune regulation during fecal microbiota transplantation and immune checkpoint inhibitor therapy

Ninkov, M., & Vareki, S. M. (2026) · Nature Communications · doi:10.1038/s41467-026-76051-z · Cited by 4 · see citing works

Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment

Xu, H., Cao, C., Ren, Y., Weng, S., Liu, L., Guo, C., Wang, L., Han, X., Ren, J., & Liu, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.949490 · Cited by 105 · see citing works

Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy

Yang, Y., An, Y., Dong, Y., Chu, Q., Wei, J., Wang, B., & Cao, H. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.104967 · Cited by 79 · see citing works

Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers

McQuade, J. L., Ologun, G. O., Arora, R., & Wargo, J. A. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00913-y · Cited by 63 · see citing works